Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

Marqibo upon successful completion of rALLy and mark another in a series of milestone achievements in recent months that underscore our ability to execute in terms of product development."

"These exciting data bring us another step closer to making this promising treatment available to this very sick ALL patient population for whom there are currently no approved or standard therapies," stated Anne Hagey, M.D., vice president and chief medical officer. "Marqibo may enable high-potency dosing of vincristine chemotherapy and improve efficacy versus standard vincristine without increased toxicity."

Yesterday, Hana Biosciences announced the findings from a planned, pre-specified safety review of data from the rALLy trial conducted by an Independent Data Monitoring Committee (IDMC). The IDMC meeting outcome supports an acceptable, manageable safety profile for Marqibo with no new safety concerns. The IDMC has recommended that the trial continue to completion per the protocol. The Company has now accrued greater than 75 percent (43 patients) of the total target enrollment of 56 patients and recruitment is on target to complete by mid-2009.

The primary objective of the rALLy study is to assess the efficacy of single-agent, weekly Marqibo (2.25 mg/m2) with dosing based on actual body surface area without the dose capping applied to standard vincristine. Secondary objectives include evaluation of safety, response duration, and survival. The patient population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation. The rALLy trial is currently being conducted at thirty-one clinical sites in the U.S., Canada, Germany, Israel and the United Kingdom.

Hana Biosciences has received orphan drug and fast track designations for Marq
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... WASHINGTON , July 30, 2015  Today we bring you a special edition ... wanted to remind you about some of our Medicare resources and continue highlighting the ... Check out our latest infographics and videos ... ... ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... LOS ANGELES, Sept. 12, 2011 Cytta Corp (OTCQB: ... successfully completed the first client installation and deployment of ... Company to commence a full scale roll out of ... payors and providers, such as: Health Plans, Managed Care ...
... - Digital issue looks inside the ... The Journal of Emergency Medical Services ( ... four-volume digital issue featuring first-person accounts of responders who were ... 2001, when terrorists invaded their response districts - and their ...
Cached Medicine Technology:First Client Installation of CyttaConnect™ Medical Monitoring System 2First Client Installation of CyttaConnect™ Medical Monitoring System 3Out of the Darkness 2Out of the Darkness 3
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... half of 2015. , Total sales were up 16 percent year-over-year for the first ... and CEO Antonio Civitella said he expected Transfinder to beat last year’s record-revenue mark ...
(Date:7/31/2015)... ... ... Creating one of the most modern fertility centers in the Middle East, ... the boundaries of fertility medicine. , As the leading gynecology and fertility hospital ... affordable treatments, unending hope, and high fertility success rates — all contributing to its ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t ... the industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International ... event attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Girl ... stamp out bullying across Georgia through the Girl Scout "Be a Friend First" program. ... on Thursday, July 30. , “Peach State Health Plan and our parent company, ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... firm, has been recognized in the 2015 Aster Awards national competition for a ... organization serving Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... an opportunity for,growth beyond San Antonio, KGS Bikes, ... is expanding into the Dallas area. They will ... month in the,new market in order to meet ... The fitting process involves a dynamic session ...
... with Retirement Accounts Would Borrow From Funds to Cover ... ... worries stemming,from current economic conditions, it appears that U.S. employees are just,as ... to an unexpected illness or injury, according to a recent survey,from Berkshire ...
... many X-rays, CT scans and nuclear medicine tests led ... -- Long-term buildup of radiation resulting from repeated emergency ... at an increased risk for developing cancer, new research ... currently in widespread use in hospitals across the United ...
... CHAPEL HILL The University of North Carolina at ... of Health (NIH) grant that will help speed up ... North Carolina. , UNC is among 14 academic ... of the NIHs Clinical and Translational Science Award (CTSA) ...
... at major worldwide congresses prior to ECLU, the ... from a comprehensive review of the latest cutting-edge ... the field. , The conference includes extensive opportunities ... experience exchange. , Highlights sessions: a ...
... Gifted Song Stylist, International Award Winning ... Breast Cancer, DALLAS, May 29 Susan G. ... three of today,s prominent African-American,leaders -- each with different ... that is empowering people around the globe to help,end ...
Cached Medicine News:Health News:KGS Bikes Offers Fittings to Dallas' Discriminating Cyclists 2Health News:KGS Bikes Offers Fittings to Dallas' Discriminating Cyclists 3Health News:Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability 2Health News:Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability 3Health News:Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability 4Health News:Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability 5Health News:Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability 6Health News:Certain Tests in ERs Raise Cancer Risk for Some 2Health News:Certain Tests in ERs Raise Cancer Risk for Some 3Health News:Certain Tests in ERs Raise Cancer Risk for Some 4Health News:New federally-funded health initiative to speed benefits of science to North Carolinians 2Health News:ESMO Conference Lugano 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 3Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 4
10-mm (0.4-in) diameter cups have multi-color lead wires and 2-mm (0.08-in) holes for easy paste/collodion application. Available in a variety of lengths to suit many different needs....
... Made with elastic fabric, these head cap ... need to begin testing. Each Electro-Cap System ... the International 10-20 System. When you place ... are using with your head cap system ...
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... head cap systems are packaged to provide ... Electro-Cap System features pure tin electrodes positioned ... you place your order, please specify which ... cap system and whether you want regular ...
Medicine Products: